Company Overview - Euronet Worldwide (EEFT) shares have decreased by approximately 2.9% since the last earnings report, although this performance has outpaced the S&P 500 [1] - The consensus estimate for Euronet Worldwide has shifted downward by 19.61% over the past month, indicating a negative trend in earnings expectations [2] Performance Metrics - Euronet Worldwide has an average Growth Score of C and a Momentum Score of D, but it received an A grade for value, placing it in the top quintile for this investment strategy [3] - The aggregate VGM Score for Euronet Worldwide is B, which is relevant for investors not focused on a single strategy [3] Outlook - The overall trend for estimates has been downward, suggesting a negative shift in expectations for Euronet Worldwide [4] - Despite the downward revisions, Euronet Worldwide holds a Zacks Rank of 2 (Buy), indicating an expectation of above-average returns in the coming months [4] Industry Comparison - Euronet Worldwide is part of the Zacks Financial - Miscellaneous Services industry, where another player, Royalty Pharma (RPRX), has seen a slight gain of 0.7% over the past month [5] - Royalty Pharma reported revenues of $742 million for the last quarter, reflecting a year-over-year increase of 0.8% [5] - For the current quarter, Royalty Pharma is projected to post earnings of $1.02 per share, which represents a 4.1% increase from the previous year [6]
Why Is Euronet Worldwide (EEFT) Down 2.9% Since Last Earnings Report?